CD1a, Thymocytes Antibody
- Known as:
- CD1a, Thymocytes Antibody
- Catalog number:
- MAB418P
- Product Quantity:
- 5 ml
- Category:
- -
- Supplier:
- INNOVEX
- Gene target:
- CD1a Thymocytes Antibody
Related genes to: CD1a, Thymocytes Antibody
- Gene:
- CD1A NIH gene
- Name:
- CD1a molecule
- Previous symbol:
- CD1
- Synonyms:
- -
- Chromosome:
- 1q23.1
- Locus Type:
- gene with protein product
- Date approved:
- 1988-05-11
- Date modifiied:
- 2017-07-07
Related products to: CD1a, Thymocytes Antibody
Related articles to: CD1a, Thymocytes Antibody
- Langerhans cell sarcoma (LCS), malignant indeterminate dendritic cell tumor (IDCT), and interdigitating dendritic cell sarcoma (IDCS) are rare malignant neoplasms that originate from antigen-presenting conventional dendritic cells (cDCs). These tumors, collectively termed cDC sarcoma in this study, have been reported only rarely in association with myeloid malignancies. We collected five cases of cDC sarcoma coexisting with acute myeloid leukemia (AML) or myelodysplastic neoplasm with increased blasts (MDS-IB), conducted clinicopathologic and genetic analyses, and compared these with four reported cases. Among the nine cases, histological subtypes included LCS (n = 6), malignant IDCT (n = 2), and IDCS (n = 1), whereas associated myeloid neoplasms comprised AML (n = 8) and MDS-IB2 (n = 1). Clinically, five patients developed cDC sarcoma and AML/MDS-IB nearly simultaneously, whereas four developed AML after cDC sarcoma. Six patients died or required palliative care within 2 years, whereas three achieved complete remission or long-term survival. Nodal involvement predominated (8/9 cases). Immunohistochemically, cDC sarcomas frequently expressed myeloid markers (CD33 5/5; CD34 2/8). Conversely, myeloid blasts expressed histiocytic/monocytic-associated markers including CD68 and lysozyme in 3/5 cases, whereas S-100 and CD1a were focally expressed in only one case. Genetically, next-generation sequencing revealed shared mutations-including those in the RAS-MAPK pathway-in four of five paired cases. Further, one case harbored a shared KMT2A rearrangement, which supports a common clonal origin. These results indicate a close biological relationship between cDC sarcoma and myeloid neoplasms and highlight the importance of recognizing concomitant myeloid disease in patients with cDC sarcoma. - Source: PubMed
Publication date: 2026/09/02
Yoshikawa KanaeSeki MasafumiSakakibara AyakoArai YoshifumiFujino MasahikoFujiki YutoUshijima YokoIshikawa YuichiNakamura ShigeoYasuda TakahikoKarube Kennosuke - Langerhans cell histiocytosis (LCH) is a rare histiocytic neoplasm that may present with isolated cutaneous involvement or multisystem disease. In adults, cutaneous manifestations are often polymorphic and may mimic more common dermatologic conditions, leading to delayed diagnosis. A 41-year-old woman with a history of treated breast carcinoma presented with a two-year history of chronic erosive lesions involving the vulvar and intertriginous regions. Additional lesions affected the scalp, retroauricular folds, umbilicus, and external auditory canals. Histopathological examination of a vulvar biopsy, supported by positive CD1a and S100 immunostaining, confirmed the diagnosis of LCH. A comprehensive extension workup revealed no evidence of visceral, pulmonary, lymph node, or skeletal involvement. The patient was treated with topical clobetasol propionate, local wound care, and treatment of secondary bacterial superinfection, resulting in marked improvement of the vulvar and intertriginous lesions during follow-up. Adult cutaneous LCH remains a diagnostic challenge because of its ability to mimic inflammatory and infectious dermatoses, particularly when flexural and genital areas are affected. Histopathological examination with immunohistochemical confirmation is essential for establishing the diagnosis and guiding further evaluation. LCH should be considered in the differential diagnosis of persistent erosive vulvar and intertriginous lesions that are unresponsive to conventional therapies. Early biopsy is crucial to avoid diagnostic delay and to ensure appropriate staging and management. - Source: PubMed
Publication date: 2026/08/02
El Yamani LamisHormi OuissalMoujahid SalmaImam KhadijaZerrouki NassibaZizi Nada - Generalized eruptive histiocytosis (GEH) is a rare non-Langerhans cell histiocytosis characterized by multiple symmetrical papular eruptions. We describe an atypical presentation of GEH in a 60-year-old man with scattered S-100 immunopositivity and seropositivity for anti-nRNP/Sm antibodies. Histopathology revealed dense perivascular and interstitial infiltrates of histiocytes, plasma cells, and occasional eosinophils within the upper to mid-dermis, while immunohistochemistry revealed diffuse CD68 positivity, CD1a negativity, and scattered S-100 positivity. The unusual immunophenotype and concurrent abnormal autoimmune serology results suggest a possible association between local histiocytic activation and systemic immune dysregulation. To the best of our knowledge, no previous reports have linked GEH with seropositivity for anti-nRNP/Sm antibodies. The coexistence of this serological finding with an atypical S-100+ immunophenotype in our case provides further insight into the immunopathological features of GEH. - Source: PubMed
Publication date: 2026/08/18
Du XinranPu SiyuZhu RuizhengGuo Dongjie - Langerhans cell histiocytosis (LCH) involving the hepatobiliary system can progress to sclerosing cholangitis and cirrhosis and may require liver transplantation (LT). We report a pediatric case in which hepatobiliary LCH was initially interpreted as Caroli syndrome and recurred in the liver allograft after LT. A 4-year-old girl presented with recurrent abdominal pain and imaging findings showing hepatomegaly, multifocal intrahepatic cystic changes, and tortuous bile duct dilatation. A prior needle biopsy supported congenital hepatic fibrosis with focal cirrhosis, and she underwent pediatric orthotopic LT. Explant pathology unexpectedly showed bile duct wall infiltration by S100+, CD1a+, and Langerin+ histiocytes, confirming LCH. Early post-transplant PET-CT showed no definite active extrahepatic disease. Eleven months after LT, while receiving tacrolimus-based immunosuppression, she was readmitted with abdominal pain, and CT, MRI, and PET-CT revealed multiple new hypodense and mildly hypermetabolic hepatic allograft lesions. Allograft biopsy confirmed recurrent LCH, and molecular testing was negative for BRAF V600E. The patient began vincristine and prednisone with Pneumocystis jirovecii prophylaxis; abdominal pain resolved and allograft function remained stable, with partial lesion regression on follow-up MRI. This case illustrates that hepatobiliary LCH may mimic Caroli syndrome before transplantation and can recur in the liver allograft, making complete explant histopathology, functional imaging surveillance, and prompt biopsy essential when new post-LT allograft lesions appear. - Source: PubMed
Publication date: 2026/08/17
Hu TingtingWang ChaoLiu ChengjiaSun Jianzhong - Langerhans cell histiocytosis (LCH) is a rare clonal proliferative disorder of bone marrow-derived dendritic cells that is uncommon in adults. Its clinical presentation varies depending on the organ involved. Central nervous system (CNS) involvement poses a critical therapeutic challenge because of permanent neurological dysfunction. Here, we report two contrasting cases of adult-onset LCH with distinct clinical outcomes. Case 1 involved a 36-year-old woman presenting with a persistent headache. Neuroimaging revealed a solitary osteolytic lesion in the left parietal bone with dural thickening. Surgical resection was performed, and histopathological examination revealed characteristic Langerhans cells with positive S-100 immunostaining, confirming the diagnosis of LCH limited to the calvarium. The patient was treated with bisphosphonates and remained stable without systemic involvement. Case 2 involved a 26-year-old man presenting with cognitive impairment, somnolence, polyuria, and endocrine dysfunction. Magnetic resonance imaging revealed an enhancing hypothalamic lesion. Histopathological and immunohistochemical analyses confirmed LCH with CD1a and S-100 positivity. BRAF V600E mutation was not detected via pyrosequencing. Systemic chemotherapy with cladribine resulted in partial tumor regression; however, the cognitive dysfunction persisted. These contrasting cases highlight that disease distribution, particularly CNS involvement, influences therapeutic strategies and neurological outcomes in adult LCH. Our findings emphasize that early diagnosis and proactive systemic evaluation are essential as functional recovery remains limited once neurological damage occurs, even with successful cytoreductive therapy. - Source: PubMed
Publication date: 2026/09/20
Shinohara ChiakiYonemochi TakuyaKikuchi MiyuHayashi NaokazuNozue KyokoInomoto ChieTakahashi Masamichi